These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 19768947

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.
    Miyamoto M.
    CNS Neurosci Ther; 2009; 15(1):32-51. PubMed ID: 19228178
    [Abstract] [Full Text] [Related]

  • 3. Autoimmune hepatitis in association with ramelteon.
    Fourman LT, Robert Meyer B.
    J Clin Gastroenterol; 2013 Aug; 47(7):651-4. PubMed ID: 23632362
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ramelteon: profile of a new sleep-promoting medication.
    Owen RT.
    Drugs Today (Barc); 2006 Apr; 42(4):255-63. PubMed ID: 16703122
    [Abstract] [Full Text] [Related]

  • 6. Ramelteon (Rozerem) for insomnia.
    Med Lett Drugs Ther; 2005 Nov 07; 47(1221):89-91. PubMed ID: 16267494
    [No Abstract] [Full Text] [Related]

  • 7. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M.
    Neuropharmacology; 2005 Feb 07; 48(2):301-10. PubMed ID: 15695169
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
    Roth T, Stubbs C, Walsh JK.
    Sleep; 2005 Mar 07; 28(3):303-7. PubMed ID: 16173650
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and clinical safety of ramelteon: an evidence-based review.
    Sateia MJ, Kirby-Long P, Taylor JL.
    Sleep Med Rev; 2008 Aug 07; 12(4):319-32. PubMed ID: 18603221
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [New hypnotics ramelteon for the treatment of insomniacs with circadian rhythm disturbance].
    Mishima K.
    Nihon Rinsho; 2012 Jun 07; 70(6):1069-78. PubMed ID: 22690618
    [Abstract] [Full Text] [Related]

  • 14. Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect.
    Mini L, Wang-Weigand S, Zhang J.
    Clin Ther; 2008 Jul 07; 30(7):1316-23. PubMed ID: 18691991
    [Abstract] [Full Text] [Related]

  • 15. Ramelteon: a novel approach in the treatment of insomnia.
    Reynoldson JN, Elliott E, Nelson LA.
    Ann Pharmacother; 2008 Sep 07; 42(9):1262-71. PubMed ID: 18648020
    [Abstract] [Full Text] [Related]

  • 16. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia.
    Richardson G, Wang-Weigand S.
    Hum Psychopharmacol; 2009 Mar 07; 24(2):103-11. PubMed ID: 19090503
    [Abstract] [Full Text] [Related]

  • 17. Ramelteon: a review of its use in insomnia.
    Simpson D, Curran MP.
    Drugs; 2008 Mar 07; 68(13):1901-19. PubMed ID: 18729542
    [Abstract] [Full Text] [Related]

  • 18. A Case of Unilateral Hypnic Headache: Rapid Response to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
    Arai M.
    Headache; 2015 Mar 07; 55(7):1010-1. PubMed ID: 26121162
    [No Abstract] [Full Text] [Related]

  • 19. Ramelteon and improved insomnia in alcohol-dependent patients: a case series.
    Brower KJ, Conroy DA, Kurth ME, Anderson BJ, Stein MD.
    J Clin Sleep Med; 2011 Jun 15; 7(3):274-5. PubMed ID: 21677897
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.